Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $281,500.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $22.52, for a total value of $281,500.00. Following the transaction, the chief executive officer owned 940,392 shares of the company’s stock, valued at $21,177,627.84. This represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.18, for a total value of $277,250.00.
• On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.05, for a total transaction of $150,375.00.
• On Monday, May 19th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.49, for a total value of $82,450.00.
• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.08, for a total value of $107,026.40.

Enliven Therapeutics Trading Up 3.7%

ELVN opened at $22.35 on Thursday. The stock has a 50-day moving average price of $20.24 and a 200-day moving average price of $20.25. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03. The stock has a market capitalization of $1.10 billion, a P/E ratio of -11.64 and a beta of 0.83.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). On average, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. HC Wainwright boosted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Jones Trading decreased their price target on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. Robert W. Baird raised their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, June 16th. Finally, The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research report on Monday, June 16th. They issued a “buy” rating and a $37.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $41.20.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after buying an additional 1,114 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after purchasing an additional 2,630 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Enliven Therapeutics during the 1st quarter worth about $60,000. KLP Kapitalforvaltning AS acquired a new stake in Enliven Therapeutics during the 4th quarter worth about $97,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at about $112,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.